Customize your JAMA Network experience by selecting one or more topics from the list below.
The National Institute of Allergy and Infectious Diseases (NIAID) recently launched a study to determine whether drugs that are already approved or in the late stage of clinical development might merit testing in larger clinical trials as a coronavirus disease 2019 (COVID-19) treatment.
The ACTIV-5 Big Effect Trial is a collaboration with the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program, a public-private partnership with the National Institutes of Health. The phase 2 randomized, double-blind clinical trial will compare different therapies to a common control group to see which drugs, if any, have relatively large treatment effects.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Rubin R. Study Aims to Identify Drugs That Could Be Repurposed for COVID-19. JAMA. 2020;324(20):2019. doi:10.1001/jama.2020.21726
Create a personal account or sign in to: